Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

OTHER 7NIH 2NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 2

Conditions

Neoplasm Metastasis 39Lymphoma 27Multiple Myeloma 24Colorectal Neoplasms 20Leukemia, Myeloid, Acute 18Melanoma 13Lung Neoplasms 13Prostatic Neoplasms 12Pancreatic Neoplasms 12Ovarian Neoplasms 12Breast Neoplasms 11Sarcoma 10Triple Negative Breast Neoplasms 9Lymphoma, Non-Hodgkin 9Fallopian Tube Neoplasms 9Burkitt Lymphoma 9Urinary Bladder Neoplasms 8Neuroblastoma 8Leukemia, Lymphocytic, Chronic, B-Cell 8Glioma 8Carcinoma, Non-Small-Cell Lung 8Squamous Cell Carcinoma of Head and Neck 7Myelodysplastic Syndromes 7Lymphoma, Follicular 7Endometrial Neoplasms 7Lymphoma, Large B-Cell, Diffuse 6Cholangiocarcinoma 6Central Nervous System Neoplasms 6Stomach Neoplasms 5Small Cell Lung Carcinoma 5

Interventions

Vincristine 4Prednisone 3MLN 8237 3Doxorubicin 3Cyclophosphamide 3temsirolimus 2romidepsin 2Specimen Handling 2Sirolimus 2Rituximab 2Lenalidomide 2Lactones 2Etoposide 2Depsipeptides 2Biopsy 2veliparib 1tipifarnib 1tazemetostat 1talimogene laherparepvec 1siplizumab 1pegaspargase 1molibresib 1merphos 1liposomal doxorubicin 1entinostat 1dexamethasone acetate 1dexamethasone 21-phosphate 1belinostat 1avelumab 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Lymphoma, T-Cell × Biopsy × Clear all
NCT02978625 2026-05-13

Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers

National Cancer Institute (NCI)

Phase 2 Active not recruiting
68 enrolled
DermatologicLymphoid

Microcystic adnexal carcinoma, Adenocarcinoma, Papillary, Carcinoma, Basal Cell, Carcinoma, Basosquamous, Mycosis Fungoides, Paget Disease, Extramammary, Sezary Syndrome, Carcinoma, Merkel Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Carcinoma, Signet Ring Cell, Muir-Torre Syndrome, Eccrine Porocarcinoma

NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡